2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007020220v1 18/10/2644    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foley, R. N. Articles by Collins, A. J. Search for Related Content PubMed PubMed Citation Articles by Foley, R. N. Articles by Collins, A. J.

End-Stage Renal Disease in the United States: An Update from the United States Renal Data System

United States Renal Data System Coordinating Center, Minneapolis, Minnesota

Correspondence: Dr. Robert N. Foley, United States Renal Data System, 914 South 8th Street, Suite S-253, Minneapolis, MN 55404. Phone: 612-347-5811; Fax: 612-347-5878; E-mail: rfoley{at}usrds.org

Patients with ESRD consume a vastly disproportionate amount of financial and human resources. Approximately 0.03% of the US population began renal replacement therapy in 2004, an adjusted incidence rate of 339 per million. Declining incidence rates were observed for most primary causes of ESRD and in most major demographic categories; the worry is that rates of diabetic ESRD continue to rise in younger black adults. Although diabetes and hypertension remain the most commonly reported cause of ESRD, rates of end-stage atherosclerotic renovascular disease seem to be on the rise in older patients. Although clinical care indicators, such as the proportion of hemodialysis patients using fistulas, continue to improve gradually, the proportion of patients overshooting target hemoglobin levels under epoetin therapy may be a source of concern. Survival probabilities have improved steadily in the US ESRD population since the late 1980s, which is remarkable when one considers the ever-expanding burden of comorbidity in incident patients. However, although first-year dialysis mortality rates have clearly improved since 1987, meaningful improvements do not seem to have accrued since 1993, in contrast to steady annual improvements in years 2 through 5. Although most of these findings are grounds for cautious optimism, the same cannot be said for issues of cost; reflecting the growth in the size of the ESRD population, associated costs grew by 57% between 1999 and 2004 and now account for 6.7% of total Medicare expenditures.

This article has been cited by other articles:

				R. Perez-Garcia, A. Martin-Malo, J. Fort, X. Cuevas, F. Llados, J. Lozano, F. Garcia, and on behalf of all Investigators from the ANSWER stu Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study Nephrol. Dial. Transplant., November 24, 2008; (2008) gfn464v2. [Abstract] [Full Text] [PDF]

				G. Eknoyan MD Progress and promise in the management of chronic kidney disease Can. Med. Assoc. J., November 18, 2008; 179(11): 1107 - 1108. [Full Text] [PDF]

				S. Maeda Review: Genetics of diabetic nephropathy Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 363 - 371. [Abstract] [PDF]

				L. S. Dalrymple and A. S. Go Epidemiology of Acute Infections among Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1487 - 1493. [Abstract] [Full Text] [PDF]

				D. C. Mendelssohn, S. K. Mujais, S. D. Soroka, J. Brouillette, T. Takano, P. E. Barre, B. V. Mittal, A. Singh, C. Firanek, K. Story, et al. A prospective evaluation of renal replacement therapy modality eligibility Nephrol. Dial. Transplant., August 28, 2008; (2008) gfn484v1. [Abstract] [Full Text] [PDF]

				E. G. Neilson Baumol's Curse on Medicine J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1049 - 1053. [Full Text] [PDF]

				G. F M Strippoli, S. D Navaneethan, D. W Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and J. C Craig Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ, March 22, 2008; 336(7645): 645 - 651. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673